LLY

718.76

-3.71%↓

JNJ

146.36

-1.52%↓

UNH

312.46

-1.93%↓

ABBV

179.78

-4.69%↓

NVO

64.27

-1.68%↓

LLY

718.76

-3.71%↓

JNJ

146.36

-1.52%↓

UNH

312.46

-1.93%↓

ABBV

179.78

-4.69%↓

NVO

64.27

-1.68%↓

LLY

718.76

-3.71%↓

JNJ

146.36

-1.52%↓

UNH

312.46

-1.93%↓

ABBV

179.78

-4.69%↓

NVO

64.27

-1.68%↓

LLY

718.76

-3.71%↓

JNJ

146.36

-1.52%↓

UNH

312.46

-1.93%↓

ABBV

179.78

-4.69%↓

NVO

64.27

-1.68%↓

LLY

718.76

-3.71%↓

JNJ

146.36

-1.52%↓

UNH

312.46

-1.93%↓

ABBV

179.78

-4.69%↓

NVO

64.27

-1.68%↓

Search

Smith & Nephew PLC ADR

Atvērts

28.04 -0.67

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

28.01

Max

28.36

Galvenie mērījumi

By Trading Economics

Ienākumi

-18M

196M

Pārdošana

156M

3B

P/E

Sektora vidējais

30.255

56.602

Dividenžu ienesīgums

2.64

Peļņas marža

6.571

Darbinieki

17,349

EBITDA

197M

717M

Rekomendācijas

By TipRanks

Rekomendācijas

Pirkt

Prognoze 12 mēnešiem

+1.27% upside

Dividendes

By Dow Jones

Dividenžu ienesīgums

Sektora vidējais

2.64%

2.45%

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

-496M

12B

Iepriekšējā atvēršanas cena

28.71

Iepriekšējā slēgšanas cena

28.04

Tehniskais rādītājs

By Trading Central

Pārliecība

Bullish Evidence

Smith & Nephew PLC ADR Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2025. g. 13. maijs 23:20 UTC

Peļņas

Aristocrat Leisure Boosts Half-Year Dividend, Keeps Focus on M&A

2025. g. 13. maijs 23:48 UTC

Tirgus saruna

Gold Edges Higher, Supported by Signs of Mild U.S. Inflation -- Market Talk

2025. g. 13. maijs 23:43 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2025. g. 13. maijs 23:43 UTC

Tirgus saruna

Nikkei May Rise on Hopes for Improving U.S.-China Trade Relations -- Market Talk

2025. g. 13. maijs 23:24 UTC

Tirgus saruna
Peļņas

Global Equities Roundup: Market Talk

2025. g. 13. maijs 23:24 UTC

Tirgus saruna
Peļņas

Aristocrat's 1H Result Falls Short, Jefferies Says -- Market Talk

2025. g. 13. maijs 22:58 UTC

Peļņas

Table: Samsung Fire & Marine 1Q Consolidated Net KRW609.03B Vs KRW701.95B

2025. g. 13. maijs 22:58 UTC

Peļņas

Samsung Fire & Marine Insurance Co. Ltd. 1Q Consolidated Net KRW609.03B Vs KRW701.95B

2025. g. 13. maijs 22:58 UTC

Peļņas

Samsung Fire & Marine Insurance Co. Ltd. 1Q Consolidated Op Pft KRW792.36B Vs Op KRW897.06B

2025. g. 13. maijs 22:58 UTC

Peļņas

Samsung Fire & Marine Insurance Co. Ltd. 1Q Consolidated Rev KRW6.106T Vs KRW5.507T

2025. g. 13. maijs 22:38 UTC

Peļņas

Aristocrat: Continues to Actively Pursue Strategic M&A Activities

2025. g. 13. maijs 22:38 UTC

Peļņas

Aristocrat: Remains Committed to Capital Management Strategy, Ongoing Share Buy-Back Program

2025. g. 13. maijs 22:37 UTC

Peļņas

Aristocrat: Expects More Operating Momentum in 2H Amid Product Rollout, Technology Initiatives

2025. g. 13. maijs 22:36 UTC

Peļņas

Aristocrat: Sees Accelerating Performance at Interactive Unit Toward FY 2029 US$1 Bln Revenue Target

2025. g. 13. maijs 22:35 UTC

Peļņas

Aristocrat: Expects Continued Market Share Gains from Gaming Unit

2025. g. 13. maijs 22:34 UTC

Peļņas

Aristocrat: Expects to Deliver NPATA Growth Over the Full Year on a Constant Currency Basis

2025. g. 13. maijs 22:33 UTC

Peļņas

Aristocrat: Interactive Business Delivered Strong Revenue Growth

2025. g. 13. maijs 22:33 UTC

Peļņas

Aristocrat: Gaming Unit Continued to Deliver Market Share Gains

2025. g. 13. maijs 22:33 UTC

Peļņas

Aristocrat: Product Madness' Key Social Casino Franchises Continued to Outperform

2025. g. 13. maijs 22:30 UTC

Peļņas

Aristocrat Interim Dividend 44 Australian Cents/Share

2025. g. 13. maijs 22:30 UTC

Peļņas

Aristocrat 1H Statutory Net Profit from Continuing Operations A$511 Mln, Down 21.6%

2025. g. 13. maijs 22:29 UTC

Peļņas

Aristocrat 1H Normalized Operating Revenue A$3 Bln, Up 8.7%

2025. g. 13. maijs 22:28 UTC

Peļņas

Aristocrat 1H Normalized Net Profit A$733 Mln, Up 5.6%

2025. g. 13. maijs 21:15 UTC

Peļņas

Nu Holdings 1Q Rev $3.2B >NU

2025. g. 13. maijs 21:03 UTC

Top Ziņas

GOP Mega Bill's Details Are Out. Now the Fighting Begins. -- WSJ

2025. g. 13. maijs 20:50 UTC

Tirgus saruna

Basic Materials Roundup: Market Talk

2025. g. 13. maijs 20:32 UTC

Peļņas

Alcon Raises 2025 View To Sales $10.4B-$10.5B >ALC.EB

2025. g. 13. maijs 20:31 UTC

Peļņas

Alcon 1Q Sales $2.45B >ALC.EB

2025. g. 13. maijs 20:30 UTC

Peļņas

Alcon 1Q Rev $2.47B >ALC.EB

2025. g. 13. maijs 20:30 UTC

Peļņas

Alcon 1Q EPS 70c >ALC.EB

Salīdzinājums

Cenas izmaiņa

Smith & Nephew PLC ADR Prognoze

Cenas mērķis

By TipRanks

1.27% augšup

Prognoze 12 mēnešiem

Vidējais 28.8 USD  1.27%

Augstākais 30.7 USD

Zemākais 27.71 USD

Pamatojoties uz 3 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Smith & Nephew PLC ADR — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt

3 ratings

1

Pirkt

2

Turēt

0

Pārdot

Tehniskais rādītājs

By Trading Central

26.64 / 28.37Atbalsts un pretestība

Īstermiņā

Bullish Evidence

Vidējā termiņā

Bullish Evidence

Ilgtermiņā

Bullish Evidence

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par Smith & Nephew PLC ADR

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. It operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products. It also provides sports medicine joint repair products comprise instruments, technologies, and implants to perform minimally invasive surgery, as well as treating soft tissue injuries and degenerative conditions of the shoulder, knee, hip, and small joints. In addition, the company offers arthroscopic enabling technologies comprising fluid management equipment for surgical access, high-definition cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue; and ear, nose, and throat solutions. Further, it provides advanced wound care products for the treatment and prevention of acute and chronic wounds, which comprise leg wounds, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, such as biologics and other bioactive technologies for debridement and dermal repair/regeneration, and regenerative medicine products, including skin, bone graft, and articular cartilage substitutes; and advanced wound devices, such as traditional and single-use negative pressure wound therapy, and hydrosurgery systems. The company serves the healthcare providers. Smith & Nephew plc was founded in 1856 and is headquartered in Watford, the United Kingdom.